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The contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic cells is one
of the major concerns in the manufacturing and quality control of hCTPs. However, no quantitative
method for detecting the tumorigenic cellular impurities is currently standardized. NOD/Shi-scid
IL2Rgnull (NOG) mice have shown high xeno-engraftment potential compared with other well-known
immunodeﬁcient strains, e.g. nude mice. Hypothesizing that tumorigenicity test using NOG mice could
be a sensitive and quantitative method to detect a small amount of tumorigenic cells in hCTPs, we
examined tumor formation after subcutaneous transplantation of HeLa cells, as a model of tumorigenic
cells, in NOG mice and nude mice. Sixteen weeks after inoculation, the 50% tumor-producing dose
(TPD50) values of HeLa cells were stable at 1.3  104 and 4.0  105 cells in NOG and nude mice,
respectively, indicating a 30-fold higher sensitivity of NOG mice compared to that of nude mice.
Transplanting HeLa cells embedded with Matrigel in NOG mice further decreased the TPD50 value to
7.9  10 cells, leading to a 5000-fold higher sensitivity, compared with that of nude mice. Additionally,
when HeLa cells were mixed with 106 or 107 human mesenchymal stem cells as well as Matrigel, the
TPD50 values in NOG mice were comparable to those of HeLa cells alone with Matrigel. These results
suggest that the in vivo tumorigenicity test using NOG mice with Matrigel is a highly sensitive and
quantitative method to detect a trace amount of tumorigenic cellular impurities in human somatic cells,
which can be useful in the quality assessment of hCTPs.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
rights reserved.a-ku, Tokyo 158-8501, Japan.
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Cell-processed therapeutic products (CTPs) derived fromhuman
somatic/stem cells are eagerly expected to treat patients with se-
vere diseases involving functional damage of organs and tissues. To
transplant hCTPs into patients, however, tumorigenicity is raised as
one of the issues of these products. Tumorigenicity is deﬁned as the
capacity of a cell population transplanted into an animal model tosting by Elsevier B.V. All rights reserved.
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or at a distant site by metastasis [1]. Assessment of tumorigenicity
is quite important to manufacture products with consistent quality.
Currently, the World Health Organization (WHO) Technical Report
Series (TRS) No. 878 Annex 1 is the only international guideline that
addresses tumorigenicity tests of animal cells for the production of
biologicals. However, the tumorigenicity test described in WHO
TRS 878, which involves the administration of 107 cells to ten nude
mice, would not be sensitive enough to detect a trace amount of
tumorigenic cellular impurities in hCTPs [2]. In addition, the in vivo
tumorigenicity test proposed in WHO TRS 878 covers only viable
animal cells used as cell substrates for manufacturing biological
products but not cells used directly for therapy by transplantation
into patients. Thus, to date, no suitable tumorigenicity test has been
established for hCTPs.
To establish methods to detect a trace amount of tumorigenic
cellular impurities in hCTPs, the usage of several newgenerations of
highly immunodeﬁcient animal models are proposed. Rag2-gC
double-knockout mice [3], NOD/Shi-scid IL2Rgnull (NOG) mice [4],
and NOD/SCID/IL-2rgKO (NSG) mice [5] indicate multiple immu-
nodeﬁciencies, including defects in T, B, and natural killer (NK) cells,
and a reduction in the function of macrophages and dendritic cells.
NOGmice exhibit extremely high engraftment rates of human HeLa
S3 cells compared with T-cell-deﬁcient nude mice and T and B-cell-
deﬁcient SCID mice [6]. NSG mice are reported to show efﬁcient
tumor formation by single human melanoma cells in combination
with Matrigel, a basement membrane-like extracellular matrix
extract [7]. However, for the use of these highly immunodeﬁcient
mouse strains to detect tumorigenic cellular impurities in hCTPs as
a part of the quality assessment/control, the performance of the
tumorigenicity tests using these strains shall be validated using
well known tumor cell lines.
In the present study, we examined the tumor formation po-
tential of HeLa cells transplanted in NOG mice with Matrigel and
compared their tumorigenicity with that in nude mice. To deter-
mine the sensitivity for the detection of tumor cells contamination
in non-tumorigenic human somatic cells, we mixed various dose of
HeLa cells in human mesenchymal stem cells and conducted
tumorigenicity tests using NOG mice and Matrigel. We also per-
formed soft agar colony formation assay, which is commonly used
to detect anchorage-independent cell growth in vitro, and
compared tumor cell detection level by soft agar with the in vivo
tumorigenicity test.
2. Materials and methods
2.1. Cells
Human cervical cancer HeLa cells were obtained from the
Health Science Research Resources Bank (HSRRB, Osaka, Japan). The
cells were maintained in Eagle's minimum essential medium
(Sigma), supplemented with 10% fetal bovine serum (FBS; Sigma),
0.1 mM non-essential amino acids (Life Technologies), 50 U/ml
penicillin, and 50 mg/ml streptomycin (Life Technologies). Human
mesenchymal stem cells (hMSCs) were purchased from Lonza and
cultured in MSCGM™ medium (Lonza). Cells were cultured in a
humidiﬁed atmosphere of 5% CO2 and 95% air at 37 C, and were
passaged upon reaching 80% conﬂuence. hMSCs were used at
passage 6 and passages 6e8 for in vivo tumorigenicity tests and soft
agar colony formation assay, respectively.
2.2. Preparation of cell suspensions for transplantation
Upon reaching approximately 80% conﬂuence, cells were
washed twice with phosphate buffered saline (PBS) and treatedwith 0.25% trypsin-EDTA solution (Life Technologies) for detach-
ment from culture dishes. HeLa cells and/or hMSCs were counted
and prepared in 100 ml of ice-cold HeLa cell culture medium or a 1:1
(v/v) mixture of HeLa cell culture medium and Matrigel (product
#354234, BD Biosciences, San Jose, CA) for transplantation.
2.3. Tumorigenicity test with immunodeﬁcient mice
Male BALB/cA nu/nu mice (nude; CLEA Japan, Inc., Tokyo) and
male NOG mice maintained in the Central Institute for Experi-
mental Animals (CIEA, Kanagawa, Japan) were used for in vivo
tumorigenicity studies. Prepared cell suspensions were injected
using 1 ml syringes with a 25 G needle (Terumo) into 8-week-old
mice (n ¼ 6 or 10). The mice were palpated weekly for 16 weeks to
observe nodule formation at the injection site. Tumor size was
assessed by external measurement of the length and width of the
tumors in two dimensions using a caliper as soon as tumors
reached measurable size. The tumor volume (TV) was calculated
using the formula volume ¼ 1/2  length (mm)  (width [mm])2.
The successive engraftment was determined according to pro-
gressive nodule growth at the injection site. Mice were euthanized
and necropsied when tumors reached approximately 20 mm in any
dimension or when a sign of deconditioning was noted. The
tumorigenicity of HeLa cells was evaluated by measuring tumor-
forming capacity, which indicates the tumorigenic phenotype
[8,9]. Tumor-forming capacity is deﬁned as 50% tumor-producing
dose (TPD50), which represents the threshold dose of cells form-
ing tumors in 50% of the animals. TPD50 values were calculated
using the Spearman-K€arber method [10e12] at each time point.
Not all animals transplanted with the highest dose formed tumors,
in which case it was assumed that the tumor incidence of animals
at 10 or 100 times the uppermost dose step (a dummy set of data)
would have been 100% for the Spearman-K€arber method to be
applicable [12].
The protocol of the present study was reviewed beforehand and
approved by the Animal Ethics Committees of CIEA (Permit Num-
ber: 13041A) and the National Institute of Health Sciences (NIHS,
Tokyo) (Permit Number: 359, 359-1, 359-2, 359-3). All animal ex-
periments were performed according to the Ethical Guidelines for
Animal Experimentation from the CIEA and the NIHS. All animals
were sacriﬁced under isoﬂurane inhalation anaesthesia, and all
efforts were made to minimize suffering.
2.4. Histology and immunohistochemistry
The engrafted tumors were isolated and ﬁxed with 10% neutral
buffered formalin (Wako). The parafﬁn-embedded sections were
investigated by hematoxylin and eosin (H&E) stain and immuno-
histochemical studies using Bond-max stainers (Leica Biosystems).
Some sections were incubated at 100 C for 10 min in a target
retrieval solution consisting of 10 mM citrate buffer (ER1; Leica
Microsystems), and then placed at room temperature for 20 min.
Mouse anti-human HLA class I-A, B, C monoclonal antibody (EMR8-
5; Hokudo, Sapporo, Japan), and rabbit anti-vimentin monoclonal
antibody (SP20; Nichirei Bioscience, Tokyo) were used as the pri-
mary antibodies. The antibodies for mouse immunoglobulin were
visualized using Bond polymer reﬁne detection kits (Leica Micro-
systems). Sections were counterstained with hematoxylin.
2.5. Soft agar colony formation assay
A soft agar colony formation assay was performed using a
CytoSelect™ 96-well Cell Transformation Assay kit (CellBio labs, San
Diego, CA) as previously described [13]. Prewarmed 25 ml of
2  DMEM/20% FBS and 25 ml of 1.2% agar solution were mixed and
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for 30 min to allow the bottom agar layer to solidify. HeLa cells and
hMSCs were dissociated into a single cell suspension by treatment
with 0.25% trypsin-EDTA solution (Life Technologies) and passed
through 40 mm nylon cell strainers (BD Falcon). Next, 25 ml of cell
suspensions containing serially diluted HeLa cells (0, 10, 20, 30, 50,
and 100 cells) and hMSCs (1.0  104 cells) in DMEM/10% FBS, were
mixed with 25 ml of 2 DMEM/20% FBS and 25 ml of 1.2% agar. After
being placed on the bottom agar layer, the top agar layers were
immediately solidiﬁed at 4 C for 10 min to avoid false-positive
signals derived from sedimentation-induced contact between the
cells. The plates were incubated with 100 ml of DMEM/10% FBS per
well for 10 and 20 days at 37 C and 5% CO2. The medium was
changed every 2e3 days. Colonies were lysed and quantiﬁed with
CyQuant GR dye using a ﬂuorometer equipped with a 485/520 nm
ﬁlter set (Wallac 1420 ARVOsx multilabel counter, PerkinElmer,
Boston, MA). Results were evaluated as a relative fold change of the
value of negative control (hMSCs only). The lower limit of detection
(LLOD) of the assay signal was calculated as the mean plus 3.3 fold
the standard deviation of the measurement of the three lots of
hMSCs [14].
3. Results
3.1. The tumorigenic potential of HeLa cells in nude and NOG mice
We ﬁrst tried to evaluate the tumorigenic potential of human
tumorigenic cells in NOG mice in the absence or presence of
Matrigel, compared with that in nude mice. Namely, we examined
the tumor formation of HeLa cells transplanted into the subcu-
taneous spaces of mice, and tumorigenic incidence was compared
between nude and NOG mice for 16 weeks (Fig. 1aec and Table 1).
The development of spontaneous tumors was not observed in non-
transplant mice of either strain during the period of monitoring.
Nude mice, which are traditional standards for tumorigenicity
testing, showed no tumor formation when HeLa cells were trans-
planted at a dose of up to 1.0  105 cells. On the other hand, NOG
mice developed tumors with a lower cell transplantation dosage
(1.0  104 cells). Transplanting HeLa cells with Matrigel consider-
ably increased the tumor formation potential of HeLa cells in NOG
mice. Notably, subcutaneous transplantation of 1.0  103 HeLa cells
gave rise to tumors in NOGmicewhen embeddedwithMatrigel (10/
10 animals) but not without Matrigel (0/10 animals). Furthermore,
60% (6/10 animals) of NOG mice formed tumors within 16 weeks
when 1.0  102 HeLa cells were transplanted with Matrigel subcu-
taneously. Next, to compare tumor forming potential of nude mice
and NOG mice more quantitatively, we calculated a 50% tumor
producing dose, TPD50, of HeLa cells in NOG and nude mice. At the
end of monitoring for 16 weeks, NOG mice exhibited
TPD50 ¼ 1.3  104 when injected with HeLa cells in the absence ofFig. 1. Tumor incidence of HeLa cells in nude and NOG mice. The tumor formation of HeLa c
relationships between the dose and the tumorigenic incidence of HeLa cells in nude miceMatrigel (Table 1). As expected, tumorigenic potential of HeLa cells
was enhanced 30-fold when transplanted in NOG mice compared
with that in nudemice (TPD50¼ 4.0 105 atweek 16). Furthermore,
tumorigenic potential of HeLa cell was enhanced 5000-fold when
HeLa cells are embedded with Matrigel and transplanted in NOG
mice (TPD50¼7.9 10 atweek16) comparedwith that in nudemice
without Matrigel. Thus, NOG mice showed superior tumor forming
potential when the tumor cells are embedded with Matrigel.
Transplanted cells progressively formed a large spheroid tumor
at the inoculation site without invading host subcutaneous tissue
(Fig. 2d). Tumor mass increases in a dose- and time-dependent
manner in both mouse strains (Fig. 2aec). To conﬁrm the origin of
tumors engrafted in the NOG mice, embedded tissue sections were
stained with anti-human HLA antibody. The immunohistochemical
analysis demonstrated that the engrafted tumors originated from
human cells (Fig. 2e). No histological difference was observed be-
tween tumor in nude mice and that in NOG mice (data not shown).
3.2. Detection of tumors in NOG mice inoculated with HeLa cells
spiked into hMSCs
Next we attempted to determine the characteristics of the test
using NOG mice and Matrigel for detection of tumorigenic cellular
impurities in human somatic cells. For this end, HeLa cells (1.0 10,
1.0  102, 1.0  103, and 1.0  104) were spiked into 1.0  106
hMSCs, and then subcutaneously transplanted into NOG mice with
Matrigel. Tumor formation at the transplanted site was continu-
ously monitored for 16 weeks. Subcutaneous transplantation of
hMSCs alone in NOG mice did not generate tumor in any mice
during the monitoring period (Table 2). Within 16 weeks after
transplanation, 50% of the NOG mice (3/6 animals) generated
subcutaneous tumors derived from 1.0  102 HeLa cells spiked in
1.0  106 hMSCs (Fig. 3a). The TPD50 of HeLa cells transplanted in
NOGmicewith 1.0 106 hMSCs andMatrigel was 1.0 102 at week
16, which was almost the same as the TPD50 transplanted with
HeLa cells alone (Tables 1 and 2). These results indicated that in vivo
tumorigenicity tests using NOGmice andMatrigel are able to detect
over 0.01% HeLa cell contamination in hMSCs, which is equivalent
to a single tumor cell contamination in 10,000 somatic cells. To
determine sensitivity of tumorigenicity tests using NOG mice, we
spiked 1.0  10 (0.0001%) and 1.0  102 (0.001%) HeLa cells into
hMSCs (1.0  107 cells), which was tenfold the dose used in the
previous experiments, and subcutaneously transplanted them into
NOG mice with Matrigel. Two and out of 6 NOG mice inoculated
with 1  102 HeLa cells generated subcutaneous tumors within 16
weeks when a higher dose of hMSCs was co-transplanted (Fig. 3b).
It is of note that one out of 6 mice transplanted with 1  10 HeLa
cells and 1 107 hMSCs also showed tumor formation. The TPD50 of
HeLa cells transplanted with 1.0  107 hMSCs and Matrigel in NOG
mice was 1.8  102 at week 16 (Table 2). These results are quiteells transplanted into the subcutaneous spaces of mice was examined for 16 weeks. The
(a) and NOG without (b) or with (c) Matrigel are presented (n ¼ 10 in each group).
Table 1
Tumor-forming capacity of HeLa cells in nude and NOG mice.
Strain Group Tumor incidence at indicated HeLa cell dose at 16w TPD50 at week 16 Fold-change in TPD50
(vs. nude mice)
0 1  10 1  102 1  103 1  104 1  105 1  106 1  107
Nude HeLa 0/10a e e e 0/10 2/10 7/10 (10/10)b 4.0  105 1.0
NOG HeLa 0/10 e 0/10 0/10 4/10 10/10 e e 1.3  104 3.0  10
NOG HeLa w/MG 0/10 0/10 6/10 10/10 10/10 e e e 7.9  10 5.0  103
e: Not tested.
MG: Matrigel.
a No. of mice in which tumors formed/total no. of mice inoculated.
b Since not all animals inoculated with the highest dose (106) formed tumors, it was assumed that the tumor incidence of animals at an even higher dose step (a dummy set
of data) would have been 100% for the Spearman-K€arber method to be applicable.
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demonstrating that HeLa cells can grow under subcutaneous en-
vironments of NOG mice without signiﬁcant effect from co-
tansplanted hMSCs. Taken together, our results indicated that
in vivo tumorigenicity tests with NOGmice in the combinationwith
Matrigel has the ability to detect 100 HeLa cells spiked into hMSCs
in almost half of mice.
Morphological observation of tumors originated from HeLa cells
spiked in hMSCs and HeLa cells alone was identical (Figs. 2d and
3c). The immunohistochemical analysis of the tissue sections us-
ing anti-human HLA monoclonal antibody clearly demonstrated
that the engrafted tumors originated from human cells (Fig. 3d).
Vimentin, an intermediated ﬁlament protein, is known to express
in the process of epithelial to mesenchymal transition and is
commonly used as one of the markers of mesenchymal stem cells
[15,16]. Negative staining with anti-vimentin antibody suggested
that formed tumors were attributed to the exceeding growth of
HeLa cells (Fig. 3e).
3.3. Changes of TPD50 values depending on the time course
The tumor development of HeLa cells in nude and NOG mice
under various conditions are shown as the transition of TPD50 atFig. 2. Characterization of subcutaneous tumors formed by transplantation with HeLa cells
with various dosages of HeLa cells were presented in respective mice (a: nude; b: NOG w/o M
volume ¼ 1/2  length (mm)  (width [mm])2. The successive engraftment was determined
necropsied when tumors reached approximately 20 mm in any dimension or when a sign
tochemistry analyses of subcutaneous tumors in NOG mice formed by transplantation with
H&E (d) and HLA antibody (e) (magniﬁcation, 40; scale bars, 1 mm).weekly intervals. Nude and NOG mice inoculated with HeLa cells
without Matrigel demonstrated only a slight decrease in TPD50
values from 8 weeks following injection (Fig. 4). On the other hand,
TPD50 values rapidly decreased until 12 weeks and then almost
reached a plateau until 16 weeks when NOG mice were inoculated
with cells in combination with Matrigel. These results suggest that
Matrigel is able to support the growth of transplanted small
number of tumor cells that cannot survive without Matrigel, and a
tumor originated from small number of tumorigenic cells takes
time to form visible mass.
3.4. Soft agar colony formation assay for detection of HeLa cell
contamination
The soft agar colony formation assay is a suitable method to
monitor anchorage-independent cell growth and a well-known
in vitro assay for the detection of malignant transformed cells
[17,18]. HeLa cells enclosed by soft agar showed progressive for-
mation of colonies (Fig. 5a), whereas hMSCs did not form any col-
onies in a soft agar media with 1  104 cells/well by day 20 (Fig. 5b
and c). We next spiked several concentrations of HeLa cells into
1  104 hMSCs to determine the minimum number of HeLa cells
required for growth in a soft agar media. More than 0.2% spikedin nude and NOG mice. Growth curves of subcutaneous tumors formed by inoculation
atrigel; c: NOG w/Matrigel). The tumor volume (TV) was calculated using the formula
according to progressive nodule growth at the injection site. Mice were euthanized and
of deconditioning was noted. Representative images from histology and immunohis-
1.0  102 HeLa cells suspended in Matrigel (d and e). Serial sections were stained with
Table 2
Tumor-forming capacity of HeLa cells mixed in hMSCs in NOG mice.
Strain Group Tumor incidence at indicated HeLa cell
dose at 16w
TPD50 at
week 16
0 1  10 1  102 1  103 1  104
NOG HeLaa e e e e 6/6b ND
NOG HeLa/hMSC (1  106) 0/6 0/6 3/6 6/6 6/6 1.0  102
NOG HeLa/hMSC (1  107) 0/6 1/6 2/6 e (6/6)c 1.8  102
e: Not tested.
ND: Not determined.
a Single dose group as a positive control.
b No. of mice in which tumors formed/total no. of mice inoculated.
c Since not all animals inoculated with the highest dose (102) have formed tu-
mors, it was assumed that the tumor incidence of animals at an even higher dose
step (a dummy set of data) would have been 100% for the Spearman-K€arber method
to be applicable.
Fig. 4. Comparative development of HeLa cell tumors in nude and NOG mice under
various conditions. HeLa cell tumor development in nude and NOG mice under various
conditions are expressed as transition of TPD50 at weekly intervals. MG, Matrigel.
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Fewer HeLa cells formed detectable colonies within 20 days (0.1%:
10 cells/well). Since the LLOD is calculated as
means þ 3.3  standard deviation (SD) [14], the LLOD of the soft
agar transformation assay was 2.06 based on signals from three lots
of hMSCs as a negative control (1.0 ± 0.3 [fold over the background
signal]) (Fig. 5d). Referring to the LLOD, even the minimum number
of HeLa cells (0.1%) gave rise to distinct detectable colonies at day
20. These results indicated that the soft agar colony formation assay
was able to detect colonies generated from at least 0.1% HeLa cells
spiked into hMSCs within 20 days.
4. Discussion
The contamination of hCTPs with tumorigenic cells is an issue of
concern for product manufacture. Although immunodeﬁcient nude
mice are commonly used to assess the tumorigenicity of cell sub-
strates used for production of biological products, more sensitive
methods are required to detect a trace amount of tumorigenic
cellular impurities in hCTPs. Superior xeno-engraftment capacity of
NOGmice were previously reported using HeLa S3 cells [6]. Here, inFig. 3. Detection of tumors in NOG mice transplanted with HeLa cells spiked into hMSCs. Th
weeks, respectively. The relationships between the cell dose and the tumorigenic incidence
(n ¼ 6 in each group). Representative images from histology and immunohistochemistry an
HeLa cells mixed in 1.0  106 hMSCs suspended in Matrigel (c, d, and e). Serial sections we
100; scale bars, 500 mm).combination with Matrigel, we have further developed and quan-
titatively characterized highly sensitive in vivo tumorigenicity tests
using NOG mice to detect trace amounts of tumorigenic cellular
impurities in hCTPs. Subcutaneous transplantation into NOG mice
with Matrigel allowed inoculation with 107 cells and actually ach-
ieved detection of 0.002% and 0.0001% HeLa cells spiked into
hMSCs at probabilities of 50% and 17%, respectively. Moreover, the
TPD50 of our methods was 5000-fold higher than that of tumori-
genicity tests using traditional nude mice at 16 weeks following
injection. We also showed that soft agar colony formation assay
could detect at least 0.1% HeLa cells spiked into hMSCs within 3
weeks as a representative in vitro tumorigenicity tests.
WHO TRS 878 recommends T-cell deﬁcient nude mice for
tumorigenicity tests. However, tumorigenicity tests using nude
mice are not sensitive enough for detecting trace amounts ofe cohorts inoculated HeLa cells spiked in 106 and 107 hMSCs cells were observed for 16
of HeLa spiked in 1.0  106 (a) and 1.0  107 (b) hMSCs cells in NOG mice are presented
alyses of subcutaneous tumors in NOG mice formed by transplantation with 1.0  104
re stained with H&E (c), HLA antibody (d), and Vimentin antibody (e) (magniﬁcation,
Fig. 5. Soft agar colony formation assay of HeLa cells. HeLa cells enclosed in soft agar showed progressive formation of colonies (a), whereas hMSCs did not form any colonies in a
soft agar media with 1.0  104 cells/well by day 20 (b). Arrows indicate the colonies of HeLa cells (magniﬁcation, 100; scale bars, 250 mm). HeLa cells (0%, 0 cells; 0.1%, 10 cells; 0.2%,
20 cells; 0.3%, 30 cells; 0.5%, 50 cells; 1%, 100 cells; 3%, 300 cells; 10%, 1000 cells) were spiked into 1.0  104 hMSCs and grown in soft agar for 10 and 20 days (c). HeLa cells spiked
into hMSCs and three lots of hMSCs were grown in soft agar for 20 days (d). The lower limit of detection (LLOD) was calculated as the mean plus 3.3 fold the standard deviation of
the measurement of the three lots of hMSCs. Quantiﬁcation of the results is described in (d). Cell growth was quantiﬁed using a CytoSelect™ kit. Results were expressed as a relative
fold change of the value of negative control (hMSC lot A). Error bars represent the standard deviation of the measurements (n ¼ 3).
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6.3  104 and 3.2  106 of human tumorigenic HeLa cells and
HEK293 cells, respectively [19]. In the present study, tumorigenicity
tests using nude mice transplanted subcutaneously with HeLa cells
indicated TPD50 ¼ 4.0  105 (Table 1). Our method using NOG mice
and Matrigel tremendously improved the TPD50, and its value was
7.9  10 when transplanted with HeLa cells (Table 1). In addition to
nude mice, NOD/SCID mice are frequently used for tumor biology
and xeno-graft research. To establish the NOD/SCID mouse strain,
SCIDmutation impairing T and B cell lymphocyte development was
transferred onto a non-obese diabetic background deﬁcient in NK
cell function [20,21]. NOD/SCID mice are known to demonstrate a
high incidence of thymic lymphomas with age [22,23]. The NOG
mice used in this study were generated by mating C57BL/6J-gCnull
and NOD/Shi-scid mice [4]. The IL2 receptor common g-chain is
indispensable for IL2, IL4, IL7, IL9, IL15, and IL21 high afﬁnity
binding and signaling, and is also thought to play a key role in
mediating susceptibility to thymic lymphomas in mice [5]. NOG
mice never show the high incidence of thymic lymphomas char-
acterized in NOD/SCID mice [24], which was consistent with our
results. The incidence of thymic lymphomas often shortens the
lifespans of mice and would lead to confusing tumorigenicity test
results. Tumorigenicity tests using NOG mice are also able to
resolve the issues arising from the pathological properties of NOD/
SCID mice.
Matrigel is a tissue basement membrane matrix rich in extra-
cellular matrix (ECM) proteins that was originally isolated from the
mouse tumor the murine Engelbreth-Holm-Swarm sarcoma [25].
Matrigel is known to facilitate human tumor xenograft growth in
rodents [26], which was conﬁrmed in the present study using HeLa
cells and NOG mice, presumably by providing the extracellular
environment for tumor growth. However, Matrigel is derived frommouse cells, not of human origin. Since the human tissue-mimetic
microenvironment is preferable for the estimation of tumorige-
nicity of hCTPs in clinical settings, development of a new human-
derived ECM proteins as an alternative to Matrigel may be neces-
sary for more precise estimation of the tumorigenic properties of
hCTPs inoculated into human tissues.
Soft agar colony formation assay is an anchorage-independent
growth assay in soft agar, which is considered the most stringent
in vitro assay to detect transformed cells. In this study, the soft agar
colony formation assay was able to detect colonies generated from
at least 0.1% HeLa cells spiked into hMSCs within 20 days (Fig. 5c).
Based on a standard curve by plotting the assay signals, the LLOD,
which was calculated as 2.06 (Fig. 5d), corresponded to approxi-
mately 0.02% HeLa cell contamination. This method is easy, inex-
pensive, and time-saving, but its sensitivity to detect transformed
cells is lower compared with in vivo tumorigenicity tests using NOG
mice and Matrigel (Fig. 3aeb and Table 2). Understanding the
abilities and limitations of individual tumorigenicity tests, we need
to select appropriate tests to evaluate hCTPs.
Products derived from somatic cells, e.g. hMSCs, are extensively
developed in industry all over the world. To our knowledge, human
adult somatic cells have not yet been reported to form tumor after
clinical application until now. Although at least four research pa-
pers have previously reported the in vitro spontaneous trans-
formation of hMSCs [27e30], two of them were retracted later
because their observations turned out to have come from cross-
contamination with tumorigenic cells [31,32]. In the other two of
the four papers, the immortal growth was easily detected in vitro
[29,30], indicating that the process control to avoid cross-
contamination and the monitoring of cell growth at/after the
limit of in vitro cell age used for production would be more critical
for the quality of products derived fromhuman somatic cells, rather
S. Kusakawa et al. / Regenerative Therapy 1 (2015) 30e3736than the detection of malignant transformation during cell
processing.
HeLa cells, the oldest immortal and tumorigenic human cell line
in the history of the world, are well-characterized, currently
available almost anywhere in the world, and extensively used for a
wide variety of biomedical research. There have been many reports
of HeLa cell cross-contamination in mammalian cell lines, and the
use of HeLa-contaminated cell lines has been a big problem over
several decades [33,34]. Therefore, we employed HeLa cells as a
model of tumorigenic cellular impurities in the present study.
Alternatively, we also expect the application of our method for
detecting the tumorigenic contamination of products derived from
human pluripotent stem cells (hPSCs) as well as human somatic
cells. It is actually being attempted for hPSCs such as embryonic
stem cells to differentiate into hMSCs and they are expected to be
used as or for hCTPs [35e37]. Although a lot of allogenic applica-
tions of primary hMSCs are currently being developed, hMSCs
derived from clonal hPSCs are presumed to have an advantage of
quality control in respect to robust manufacturing and restricted
virus infection. However, since undifferentiated hPSCs are tumor-
igenic, the contamination of the ﬁnal products with residual PSCs is
one of the biggest concerns [2]. Recently, we showed that the NOG
mouse was the most sensitive animal in terms of tumor formation
from human induced pluripotent stem cells (hiPSCs) among several
immunosuppressed animals, with the TPD50 value in between 102
and 103, when injected subcutaneously with Matrigel [38]. In the
same paper, we also showed that, when hiPSCs were co-
administered with Matrigel and retinal pigment epithelial cells
derived from hiPSCs, the TPD50 value was increased to approxi-
mately 103 to 104, presumably attributable to paracrine action of
pigment epithelium-derived factor with a pro-apoptotic effect on
hiPSCs [38]. These results, combined with those in the present
study, suggest that the in vivo tumorigenicity test using NOGmice is
commonly applicable to the detection of tumorigenic or pluripo-
tent cellular impurities in a variety of hCTPs.
To our knowledge, the in vivo tumorigenicity test using NOG
mice in the present study is one of the most sensitive methods to
detect a trace amount of tumorigenic cells in normal cells. However,
hCTPs may contain quite a large number of cells in clinical setting.
In some cases of cellular therapy, one hundredmillion or more cells
are necessary [39]. For example, 1  108 or more cells are required
for the treatment of liver disease [40]. For one patient with heart
failure, preferably more than one billion cardiomyocytes need to be
transplanted [41]. The sensitivity of the assay methods in the pre-
sent study would be insufﬁcient to evaluate tumorigenicity of
hCTPs like above. The problem is that no method is currently
available to detect one or a few tumorigenic cells in more than 107
normal cells. Further studies are necessary to develop more sen-
sitive tests for hCTPs. Improvements of the tests (e.g. development
of new animal models or matrix better than Matrigel), in vivo/
in vitro tumorigenicity tests for cells cultured beyond the limit of
in vitro cell age used for production, or combinations of the tests
(e.g. in vivo test for cell colonies in soft agar) may be options.
Another problem is that scientiﬁc interpretations of the results
from in vivo tumorigenicity tests have not been established,
because the tests have not been well-characterized from a view-
point of the evaluation of hCTPs. In the present study, we quanti-
tatively characterized the in vivo tumorigenicity test, and
determined its ability of detection of a trace amount of tumorigenic
cells. According to the results in Table 2, the in vivo tumorigenicity
test using NOGmice andMatrigel detects as low as 0.0001% cellular
impurities at a probability of 17%, in case that the tumorigenicity of
the impurities is comparable to that of HeLa cells in hMSCs.
Conversely, the false negative rate (x) of an NOG mouse inoculated
with the hCTP containing the 0.0001% cellular impurities is(100e17¼) 83%. Thus, the false negative rate (y) of n mice can be
expressed as follows:
y ¼ xn
Hence, we obtain:
n ¼ log y=log x
For example, when permitting 1% false negative rate in the
whole test, 25 (¼log (0.01)/log (0.83)) mice are necessary to prove
the absence of the 0.0001% cellular impurities. In other words, if 25
or more mice are used for a tumoriginicity test, and if no tumor
formation is observed in all the mice, the test result indicates, at a
false negative rate of 1%, that the hCTPs is not contaminated with
0.0001% or more HeLa-like tumorigenic cells.
This well-characterized test can be applicable at least to quality
assessment/control of hCTPs. Namely, although “Negative in the
NOG mouse test” may not directly guarantee the “safety” of the
ﬁnal product, the negative result can be one of critical “quality”
attributes to demonstrate the absence a certain number of tumor-
igenic cells. To date, no international/domestic regulatory authority
has issued guidelines for the tumorigenicity tests of hCTPs. Further
studies are necessary to establish and share principles, paradigms,
and standardized methods for measurements and interpretations
of tumorigenicity of hCTPs, which will greatly contribute to the
development of safe hCTPs of high quality.
5. Conclusions
In this study, we have demonstrated that NOG mice in combi-
nation with Matrigel demonstrated superior efﬁciency in engraft-
ment of HeLa cells, compared with nude mice that are
recommended in WHO guideline. They also showed an ability to
detect as little as 100 HeLa cells present in hMSCs in almost half of
mice. These results suggest that the in vivo tumorigenicity test
using NOGmice with Matrigel is a highly sensitive and quantitative
method to detect a trace amount of tumorigenic cellular impurities
in human somatic cells, which can be useful in quality assessment
of hCTPs.
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